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T
his clinical update summarizes articles and guidelines
published in the last year that may impact general
internists’ clinical practice related to women’s health.
METHODS
To identify relevant articles published between March 1, 2009
and February 28, 2010, we reviewed the contents of leading
medical journals including: the New England Journal of
Medicine, the Journal of the American Medical Association,
Annals of Internal Medicine, Archives of Internal Medicine,
British Medical Journal, Lancet, Obstetrics and Gynecology,
American Journal of Obstetrics and Gynecology, Journal of
General Internal Medicine, PLOSMedicine, American Journal
of Public Health, Circulation, Diabetes, and Diabetes Care. We
also reviewed updates to the Cochrane database of systematic
reviews, Guideline Clearinghouse, and the articles highlighted
by the ACP Journal Club, Journal Watch and Journal Watch
Women’s Health. Finally, we performed a MEDLINE search
using the medical subject heading, “sex factors.” Those
abstracts rated in the top third of importance by any author
were read closely and rated by all authors. A process of
individual ratings and multiple discussions was then used to
reach consensus about the most important articles published
in the last year.
RESULTS
We identified 152 articles relevant to women’s health; 20
articles were selected for presentation at the annual meeting
and 12 for detailed discussion in this paper.
MIGRAINE AND CARDIOVASCULAR RISK
Migraine and Cardiovascular Disease: Systemic
Review and Meta-Analysis
1
What was known?. Migraines affect up to 13% of the
population and are significantly more common in women.
Up to a third of migraine patients experience aura. A 2004
meta-analysis showed a significant association between
ischemic stroke and both migraine with and without
aura.
2
What this study adds. This updated meta-analysis incorporates
data from six new studies, including three large cohort studies
(which increased the sample size from roughly 7800 patients
to over 210,000 patients). Only well-designed case-control or
cohort studies were included. The investigators found that
migraine with aura was associated with a two-fold increase in
risk for ischemic stroke (RR=2.16, 95%CI, 1.53-3.03). The
risk was higher for women than men (RR=2.08, 95%CI, 1.13-
3.84), those<45 years (RR=2.65, 95%CI, 1.41-4.97), smokers
(RR=9.03, 95%CI, 4.22-19.34), and oral contraceptive users
(RR=7.02, 95%CI, 1.51-32.68). Patients with migraine
without aura showed no increased risk. There was no
association between migraine and myocardial infarction or
cardiovascular death.
How should I change my practice?. Aggressive modification of
cardiovascular risk factors and alternatives to estrogen-
containing contraceptives should be considered for women
with migraine with aura.
OVARIAN CANCER SCREENING
Results from Four Rounds of Ovarian Cancer
Screening in a Randomized Trial
3
What was known?. Annually in the United States, over
22,000 women are diagnosed with ovarian cancer and over
15,000 die from the disease. Pro g n o s i si sg r e a t l yi m p r o v e d
with diagnosis at an early stage (Stage I or II) compared with
later stages. To date, attempts to screen for ovarian cancer
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207using either transvaginal ultrasound or CA125 tumor
marker levels have not reduced mortality.
4,5
What this study adds. This study examined whether screening
with both transvaginal ultrasound and CA125 would reduce
mortality from ovarian cancer. Over 34,000 women aged
55-74 years were randomized to annual transvaginal
ultrasound and CA125 vs. usual care for four years. If
either was positive, management was per the patient’s
personal physician. At the baseline screen, 5.8% of women
were positive for either test, 33.8% of whom (n=566)
underwent biopsy, resulting in the diagnosis of 18 new
ovarian cancers (83% were Stage III or IV). By the end of the
4
th round of screening, 42 additional invasive cancers were
diagnosed (67% late stage). With each round of screening,
the number of cancers diagnosed per 10,000 women
screened ranged from 4.7-5.9. The ratio of surgery to
invasive cancer was 31:1 at the baseline screen and
decreased to 14:1 by the end of round 4. Cases detected
by ultrasound only (normal CA125) tended to be early stage
(71% of 14 cases), but these drove most of the unnecessary
surgeries. Cases detected by elevated CA125 (regardless of
ultrasound) predicted late stage (79-89%).
How should I change my practice?. This study reinforces
current USPSTF guidelines
6 that screening for ovarian cancer
is not recommended with annual transvaginal ultrasound or
CA125 in women of average risk. It remains to be seen whether
screening will impact mortality.
BREAST CANCER RISK
New Onset Breast Tenderness After Initiation
of Estrogen Plus Progestin Therapy and Breast
Cancer Risk
7
What was known?. Combination postmenopausal hormone
therapy (PHT) has been associated with a 30% increase in
breast cancer risk in the Women’s Health Initiative (WHI)
Trial.
8 Of women who initiate PHT, up to 25% develop new-
onset breast tenderness (NOBT), perhaps linked to increased
breast cell proliferation. This NOBT has been associated with
increased mammographic density,
9 and mammographic
density is a risk factor for breast cancer.
10 Thus, it is
biologically plausible that NOBT could be associated with
breast cancer incidence.
What this study adds. T h e s ei n v e s t i g a t o r ss o u g h tt o
determine if NOBT with initiation of PHT is predictive of
breast cancer development using data from the WHI trial,
in which 16,608 women were randomized to conjugated
equine estrogens+medroxyprogesterone acetate vs. placebo.
Baseline and annual breast exams and mammograms were
performed. Breast tenderness was assessed by a four-point
Likert scale at baseline and 1st annual follow-up. After a
mean follow-up of 5.6 years, 36.1% of women taking PHT
developed NOBT vs. 11.8% of women taking placebo (RR=
3.07, 95%CI, 2.85-3.30). In the PHT group, the risk of
breast cancer was higher in women with NOBT (HR=1.48,
95%CI, 1.08–2.03). There was no association in the placebo
group.
How should I change my practice?. Information about
whether a woman develops NOBT can inform decision-
making about continuation of PHT and mammographic
screening intervals. The symptom is easy to elicit and has a
positive predictive value (2.7%) that is similar to the Gail
model. Although women taking PHT who develop NOBT have
an increased risk of invasive breast cancer, the absolute risk
remains small.
BREAST CANCER SCREENING
Screening for Breast Cancer: An Update for the U.S.
Preventive Services Task Force
11
What was known?. Breast cancer accounts for almost 1 in 4
cancers in U.S. women, and screening mammography reduces
breast cancer mortality.
12,13 However, when to start screening
mammography remains controversial. A systematic review and
meta-analysis conducted in 2002 showed a 15% relative risk
reduction among women aged 40-49;
14 however, only one of
the included trials was specifically designed to address
this issue. Additionally, the analysis did not provide a
comprehensive review of the harms associated with screening
mammography. Questions also remained about the
effectiveness of mammography in older women, and the
utility of clinical and self breast exams.
What these studies add. The United States Preventive Services
Task Force updated the 2002 meta-analysis regarding
mammography benefit in women aged 40-49 to include two
new sources of data. Pooling these data with those from the
previous meta-analysis resulted in a 15% relative risk
reduction (95%CI 0.75-0.96) in breast cancer mortality
among women aged 40-49 years. However, this was
balanced with a high number needed to invite to prevent
one breast cancer death (1904: 95%CI 929-6378) and a high
false positive rate in this age group (97.8 per 1000 screened).
Evidence was insufficient regarding the benefits of
mammography in women older than 70 and the clinical
breast exam; breast self-exam did not have any net benefit.
A model of the effectiveness of various mammographic
screening strategies for reducing breast cancer mortality
15
found that the most efficient models initiated screening at age
50 with a biennial interval. Starting screening at age 40
reduced breast cancer mortality by an additional 3% but
resulted in more false-positives, whereas biennial screening
over the age of 50 retained 81% of the benefit achieved with
annual screening.
How should I change my practice?. Screening mammography
for women aged 40-49 should not be reflexive. Biennial
s c r e e n i n gr e t a i n st h es a m eb e n e f i t sa sa n n u a ls c r e e n i n ga n d
208 Schwarz et al.: Update in Women’s Health JGIMshould be recommended for women over 50 years. The
benefits of clinical breast exam, and of mammography in
women over 70 years, remain inconclusive.
PRIMARY CARE FOR WOMEN WITH BREAST CANCER
Selective Serotonin Reuptake Inhibitors and Breast
Cancer Mortality in Women Receiving Tamoxifen:
A Population-Based Cohort Study
16
What was known?. Tamoxifen is a selective estrogen receptor
modulator used to treat breast cancer.
17 The cytochrome P450
isoenzyme CYP2D6 catalyzes the conversion of tamoxifen to its
bioactive metabolite, endoxifen.
18 Paroxetine is a potent
inhibitor of the CYP2D6 isoenzyme, which lowers serum
concentrations of endoxifen;
18 co-administration of these
medications may have clinical consequences.
What this study adds. This retrospective cohort study examined
the prescription and clinical records of 2,430 older women with
breast cancer who received simultaneous treatment with
tamoxifen and a single selective serotonin receptor inhibitor
(SSRI). Using within-drug comparisons, the investigators
examined associations between breast cancer death and co-
treatment time with tamoxifen and an SSRI. For women
treated simultaneously with tamoxifen and paroxetine,
increases of 25%, 50%, and 75% in the proportion of time
that paroxetine and tamoxifen treatment overlapped resulted
in increased risk of breast cancer death of adjusted HR=1.24
(95%CI 1.08-1.42), 1.54 (95%CI 1.17-2.03) and 1.91 (95%CI
1.26-2.89), respectively. Similar associations were not noted
for co-treatment with any other antidepressants; hazard ratios
were actually lower with increasing co-treatment time with
venlafaxine and tamoxifen
How should I change my practice?. Practitioners should avoid
prescribing paroxetine to women treated with tamoxifen.
Soy Food Intake and Breast Cancer Survival
19
What was known?. Soy foods are rich in isoflavones, which
have both estrogen and anti-estrogen effects.
20 Controversy
exists regarding the effects of soy consumption on breast
cancer risk.
20,21
What this study adds. This large, prospective cohort study,
involving 5,042 breast cancer survivors in Shanghai, assessed
the association between soy food intake and total mortality,
breast cancer mortality, and breast cancer recurrence. Soy
food and isoflavone intake were measured 18 months,
36 months, and 60 months after breast cancer diagnosis and
were grouped by quartiles. When comparing the lowest intake
quartile to the highest, increasing soy protein intake was
associated with a decreased risk for total mortality (adjusted
HR=0.71, 95%CI 0.54-0.94) and breast cancer recurrence and
mortality (adjusted HR=0.68, 95%CI 0.54-0.87). Similar
effects were noted in women with ER-positive breast cancer,
although all confidence intervals crossed 1.0. In addition,
tamoxifen use seemed to improve survival only among women
with low-moderate soy food intake, although this result was
not statistically significant.
How should I change my practice?. There is no need to
counsel breast cancer patients to avoid soy-containing foods
and beverages. The average amount of soy protein consumed
by participants in this study was 47 mg/day, which far
exceeds the average 1-6 mg/day consumed by American
women. The study resulted in new cancer screening
guidelines (Table 1).
OSTEOPOROSIS
Vitamin D and Fractures
Prevention of Nonvertebral Fractures with Oral Vitamin D
and Dose Dependency: Meta-Analysis of Randomized
Controlled Trials
22
What was known?. Vitamin D deficiency is common in older
adults, homebound individuals and women admitted with hip
fracture. The association between vitamin D levels and
fracture risk has been inconsistent, although a recent well
done case-control study showed that women with lower serum
25-OH-vitamin D levels had a higher fracture risk than women
with higher levels and there was a dose response effect.
23
Although women are frequently treated for vitamin D
deficiency, it has not been known whether vitamin D
supplementation prevents non-vertebral and hip fractures.
What this study adds. This well-done meta-analysis included
twelve studies that evaluated vitamin D supplementation and
reported at least one fracture. Studies had to be double-blind
with at least one year of follow-up and data on adherence.
Participants took either cholecalciferol (D3) or ergocalciferol (D2).
Vitamin D doses >400 IU per day reduced nonvertebral and hip
fractures but lower doses did not. The overall reduction was
relatively small (RR=0.86, 95%CI 0.77-0.96) for nonvertebral
fractures. The addition of calcium did not enhance the effect of
Vitamin D. In addition, the anti-fracture efficacy was higher with
higher achieved 25-OH vitamin D levels.
How should I change my practice?. Recommendations for
vitamin D supplementation have typically targeted the goal
of achieving a particular 25-OH-vitamin D level, rather than
a clinical outcome. We now know that vitamin D
supplementation can reduce fracture risk and should be
considered for women with osteoporosis and potentially
osteopenia. Further study is needed to clarify when
supplementation should begin and whether there is added
value to co-treatment with calcium and/or bisphosphonates.
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Value of Routine Monitoring of Bone Mineral
Density After Starting Bisphosphonate Treatment:
Secondary Analysis of Trial Data
24
What was known?. Screening bone densitometry is
recommended for women aged 65 and over as well as for
younger women with risk factors,
25 however whether bone
mineral density (BMD) should be monitored once treatment
is started is controversial.
26-28
What this study adds. This study was a reanalysis of data from
the Fracture Intervention Trial (FIT),
29 in which women were
treated with alendronate or placebo, received annual bone
densitometry and were followed for fractures. Investigators
compared “within- person” variation (measurement) with
“between-person” variation (treatment effect) in serial bone
density measurements. They found that within-person
measurement-related variation was greater than between-
person treatment- related variation, suggesting that routine
monitoring of BMD during the first three years of
bisphosphonate treatment is unnecessary. The vast majority
of individuals (97.5%) gained bone mineral density with
alendronate treatment.
How should I change my practice?. Monitoring BMD in
postmenopausal women after starting bisphosphonate
treatment for osteoporosis is not necessary. Treatment
“failure” is best described by fracture while on therapy rather
than a decrease in BMD.
TREATMENT OF OSTEOPOROTIC COMPRESSION
FRACTURES
Efficacy and Safety of Balloon Kyphoplasty
Compared with Non-Surgical Care for Vertebral
Compression Fracture (Free): A Randomized
Contolled Trial
30
What was known?. Spontaneous vertebral fractures can cause
significantmorbidity and mortality.Theuseofboth vertebroplasty
(augmentation of vertebral compression fractures with
polymethylmethacrylate (PMAA)) and kyphoplasty (inflating a
balloon to restore the vertebral body to its original height while
creating a cavity into which PMMA can be injected under low
pressure) is increasing despite little evidence to support their
use
31. There have also been reports of procedures being repeated
at previously treated levels and the use of prophylactic
vertebroplasty at levels deemed to be at high risk for fracture
32,33
What this study adds. Kyphoplasty was compared to nonsurgical
care in 300 participants in 18 countries in participants with acute
vertebral fractures of less than 3 months duration. Nonsurgical
care included back brace, walking aids, analgesics and physical
therapy. At one month follow-up, kyphoplasty recipients had
significant improvement in the SF-36 physical component, 5.2
points (95%CI 2.9-7.4) greater than those who received
nonsurgical care. At 12 months, there were no differences in
outcomes between groups, and subsequent fractures were
common in both groups (33% vs 25% control p=NS).
How should I change my practice?. In patients with acute
fractures, kyphoplasty improves pain and function at 1 month,
Table 1. Important Women’s Health Guidelines in 2009-2010: New or Updated
Topic Issuing organization Updated recommendations
Cervical Cancer Screening ACOG Cervical cancer screening should begin at age 21 regardless of the age of onset of
sexual activity
Screening should occur every 2 years in women aged 21-29 (more frequently in women
with HIV, immunosuppression, DES exposure of history of CIN)
Women aged 30 and over who have had at least 3 negative smears can be screened every
3 years (Co-testing with cervical cytology and high risk HPV typing is also appropriate;
if co-testing is negative, rescreening can occur in 3 years)
Women who have had a hysterectomy do not need cervical cancer screening
After age 65-70, screening can cease in women who have had at least 3 previous negative
tests and no abnormalities in the past 10 years
Those with CIN2, CIN3 or cancer should undergo annual screening for 20 years
Breast Cancer Screening USPSTF HPV vaccine does not change these recommendations
The decision to start regular, biennial screening mammography before the age of 50 years
should be an individual one and take patient context into account, including the patient’s
values regarding specific benefits and harms
51,52
Screening mammography is recommended every two years for all women aged 50 to 74
There is insufficient evidence to weight the benefits and harms of screening mammography
for women older than 75
The evidence for the clinical breast exam is insufficient; women should not be taught how to
do breast self-exam
ACOG American College of Obstetrics and Gynecology
CIN cervical intraepithelial neoplasia
HPV human papilloma virus
USPSTF United States Preventive Task Force
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care. Kyphoplastyappears to besafein the short term. Of note,two
recent trials showed no benefit of vertebroplasty compared with
placebo, although there was a high ra t eo fc r o s s o v e ri nt h es t u d i e s ;
it is possible that the placebo injected into the periosteum may
have had some analgesic effect and the participants had fractures
that were less acute (<12 months in duration). For individuals with
compression fractures who have failed conservative treatment,
kyphoplasty may be an option toimprovesymptoms at one month.
Longer term data on efficacy are needed.
LACTATION AND MATERNAL HEALTH
Duration of Lactation and Incidence
of the Metabolic Syndrome in Women
of Reproductive Age According to Gestational
Diabetes Mellitus Status: A 20-Year Prospective
Study in CARDIA
34
What was known?. Retrospective studies have shown that
lactation decreases a mother’s risk of developing
hypertension,
35 hyperlipidemia,
35 diabetes mellitus,
36,37 and
cardiovascular disease.
38,39 Although major US medical
organizations recommend women breastfeed each of their
children for at least 12 months,
40-42 only 24% of US women are
able to comply with this recommendation.
43
What this study adds. This prospective cohort study included
1399 nulliparous women, aged 18-30, who had no evidence of
metabolic syndrome on blood tests or blood pressure
measurements performed at the time of study enrollment. Over
twenty years of follow up, 704 women reported one or more
singleton births and 120 developed the metabolic syndrome. In
analyses controlling for age, race, education, parity, smoking,
physical activity, baseline BMI and components of metabolic
syndrome, this study found that mothers who did not lactate
were at greater risk of developing the metabolic syndrome. These
findings were particularly striking for women who had
developed gestational diabetes mellitus(GDM); those who
lactated for less than 1 month were much more likely to
develop the metabolic syndrome (HR=7.14, 1.82-25.00) than
mothers who lactated for more than 9 months after a
pregnancy affected by GDM. Among mothers who did not
lactate incident metabolic syndrome was more common among
pregnancies affected by GDM (49.4 per 1000 person-years)
than those not affected by GDM (16.7 per 1000 person-years).
In contrast, among mothers who breastfed for more than
9 months, those with GDM (8.5 per 1000 person years) were
not more likely than those without GDM (9.2 per 1000 person
years) to develop the metabolic syndrome.
How should this change my practice?. Women who
discontinue lactation before nine months postpartum are at
increased risk of developing the metabolic syndrome and may
benefit from more aggressive lifestyle modification and
screening for cardiovascular disease. Breastfeeding mothers
should be encouraged and women considering pregnancy
should be informed that breastfeeding has important effects
on both maternal and infant health.
CONTRACEPTION
Hormonal Contraception and Risk of Venous
Thromboembolism: National Follow-Up Study
44
What was known?. Estrogen-containing contraceptives
increase risk of venous thromboembolism (VTE). Concern
had been raised that some progestins may also increase risk
of VTE.
45
What this study adds. This national cohort study followed
Danish women, aged 15-49, from 1995 to 2005. Using data
from 4 linked databases, the investigators identified 4,213
first-time VTE over 10.4 million woman-years of observation.
The authors report the absolute risk of VTE in young women
u s i n go r a lc o n t r a c e p t i v e si sl e s st h a no n ep e r1 0 0 0u s e r -
years. In addition, the authors found that women using
progestin-only pills (adjusted RR=0.59, 95%CI 0.33-1.04) or
the levonorgestrel-containing intrauterine contraceptive
(aRR=0.89, 95%CI 0.64-1.26) were no more likely to
develop VTE than non-users of oral contraceptives.
However, women using estrogen containing contraceptives
were two to four times as likely as non-oral contraceptive
users to develop VTE. In models adjusted for women’sa g e ,
educational level, length of use, and calendar year, combined
oral contraceptives that contained desogestrel (aRR=1.82, 1.49-
2.22), gestodene (aRR=1.86, 1.59-2.18), or drospirenone
(aRR=1.64, 1.27-2.10) were more frequently associated
with VTE than oral contraceptives containing the progestin
levonorgestrel.
How should this change my practice?. All women seeking
contraception, and especially those at increased risk of VTE,
should be encouraged to consider highly effective reversible
o p t i o n st h a ta r ee s t r o g e n - f r e es u c ha sa ni n t r a u t e r i n e
contraceptive or a contraceptive implant; those women who
prefer to use a combined oral contraceptive should be offered a
product containing levonorgestrel, norethindrone, or
norgestimate as first line options.
Ulipristal Acetate Versus Levonorgestrel
for Emergency Contraception: A Randomised
Non-Inferiority Trial and Meta-Analysis
46
What was known?. Levonorgestrel emergency contraception
pills (ECP), which are available in the US without a
prescription to all individuals over the age of 17 as Plan B
one step or the generic, Next Choice, are at least twice as
effective as the Yuzpe regimen.
47,48 However, as unintended
pregnancy and abortion remain common,
49 the search for
better contraceptives continues.
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trial, which enrolled 2221 women from 35 clinics in the United
Kingdom, Ireland, and the USA, was designed to show that
30 mg of ulipristal acetate is non-inferior to 1.5 mg of
levonorgestrel when used as EC within 5 days of unprotected
intercourse. Adverse events were similar between groups and
included headache (19%), dysmenorrhea (14%), and nausea
(12%). Pregnancy rates with use of either ECP (1.8% with
ulipristal acetate vs 2.6% with levonorgestrel) were lower than
the 5.5 % expected without use of ECP. In a meta-analysis
which combined the results of this study with a similar
study,
50 the investigators reported that women using
ulipristal acetate for EC were less likely than women using
levonorgestrel within 5 days of unprotected sex to become
pregnant (OR=0.55, 95%CI 0.32-0.93).
How should this change my practice?. Ulipristal acetate has
recently been approved for EC use in Europe and the US (as
“ella”). Advance prescription of ulipristal acetate should be
considered for all patients using barrier methods of
contraception.
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